Metabolomics

Sapient Appoints Jonathan Usuka as Chief Business Officer

Retrieved on: 
Mardi, mai 7, 2024
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, University, Informatics, Protein, University of Pennsylvania, McKinsey & Company, NIH, AI, Princeton University, Proteomics, MD, Doctor of Philosophy, Roche, Therapy, Stanford University, Patient, Genome, MBA, Drug development, Metabolomics, Drug discovery, Analytics, Celgene, Growth

Sapient , a leading biomarker discovery organization providing at scale services for multi-omics data generation and analysis, has announced the appointment of Jonathan Usuka, PhD, MBA as Chief Business Officer, expanding its leadership team to support and further propel the company’s rapid growth.

Key Points: 
  • Sapient , a leading biomarker discovery organization providing at scale services for multi-omics data generation and analysis, has announced the appointment of Jonathan Usuka, PhD, MBA as Chief Business Officer, expanding its leadership team to support and further propel the company’s rapid growth.
  • “We are absolutely thrilled to welcome Jonathan into this critical leadership role for Sapient,” said Mo Jain, MD, PhD, Founder and CEO of Sapient.
  • Previously, Dr. Usuka was a Senior Expert at McKinsey & Company, leading their Center for Analytics and Real-world Evidence.
  • “Sapient has an amazing group of scientists and a technology approach that can revolutionize the discovery and development of novel therapeutics, and I'm honored to join in that pursuit,” said Dr. Usuka.

Wistar Scientists Discover New Immunosuppressive Mechanism in Brain Cancer

Retrieved on: 
Vendredi, mai 3, 2024
Cell, National Cancer Institute, Macrophage, Sapienza University of Rome, Genome, Glucose, Wistar Institute, Gene, Brain, Tumor microenvironment, Wistar, Metabolomics, Neuroscience, Immunity, Ben, Medical research, Microglia, Research, Proteomics, Immunology, Histone, Malignancy, Gene expression, Neoplasm, Aurelia, Cancer, Collaborative writing, DSM-IV codes, Prognosis, Immunosuppression, Immunotherapy, Duke School, Disease, GLUT1, Patient, Metabolism, Immune system, Angelica, Vaccine

The lab’s discovery was published in the paper, “ Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma ,” in the journal Immunity.

Key Points: 
  • The lab’s discovery was published in the paper, “ Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma ,” in the journal Immunity.
  • Indeed, monocyte-derived macrophages, but not microglia, blocked the activity of T cells (immune cells that destroy tumor cells), in preclinical models and patients.
  • Glioblastoma is inherently dangerous due to its location in the brain and its immunosuppressive tumor microenvironment, which renders glioblastoma resistant to promising immunotherapies.
  • Note: The work detailed in this publication was initiated at The H. Lee Moffitt Cancer Center during Dr. Veglia’s time there and continued at Wistar.

Clinical Microbiomics Launches Advanced Long-Read 16S, ITS, 18S, Isolate, and Metagenomics Sequencing Services

Retrieved on: 
Mardi, avril 23, 2024
P24, ITS, Genomics, CCO, Metagenomics, Health, Probiotic, Business development, Nielsen, ONT, Research, Disease, DNA, Acquisition, Oxford Nanopore Technologies, Metabolomics, Prebiotic (nutrition), Algorithm

COPENHAGEN, Denmark, April 23, 2024 /PRNewswire/ -- Clinical Microbiomics, a leader in microbiome analysis, announces the launch of its advanced long-read sequencing services. Tailored to meet the stringent requirements of academic, clinical, and industrial researchers, the expanded offerings deliver unmatched insights into microbial communities, featuring the industry's highest quality scores and read lengths.

Key Points: 
  • COPENHAGEN, Denmark, April 23, 2024 /PRNewswire/ -- Clinical Microbiomics , a leader in microbiome analysis, announces the launch of its advanced long-read sequencing services.
  • Anders Grøn, CEO, states, "Our enhanced long-read sequencing capabilities are redefining the standards in microbial analysis and microbiome research.
  • Dr. Henrik Bjørn Nielsen , Chief Scientific Officer, states, "Our new long-read sequencing services represent a significant advancement in microbiome research.
  • Clinical Microbiomics' long-read sequencing services are globally available, supported by state-of-the-art laboratories in Denmark and the United States.

Specialty Enzymes & Probiotics Publishes New Clinical Study on Revolutionary Sports Nutrition Ingredient DigeSEB Sport™

Retrieved on: 
Mercredi, avril 17, 2024
Digestion, Inflammation, Probiotic, Trial of the century, Research, Depression, Metabolomics, Endurance, Ageing, Anxiety, Absorption, Dietary supplement

CHINO, Calif., April 17, 2024 /PRNewswire/ -- A new clinical study shows DigeSEB Sport™, a potent sports nutrition ingredient offered by Specialty Enzymes & Probiotics, promotes protein digestion and nutrient bioavailability, a healthy gut microbiome, and the production of postbiotics, such as GABA and β-alanine.

Key Points: 
  • CHINO, Calif., April 17, 2024 /PRNewswire/ -- A new clinical study shows DigeSEB Sport™, a potent sports nutrition ingredient offered by Specialty Enzymes & Probiotics, promotes protein digestion and nutrient bioavailability, a healthy gut microbiome, and the production of postbiotics, such as GABA and β-alanine.
  • An unexpected study result found that supplementation with DigeSEB Sport™ increased the production of postbiotics GABA, L-citrulline, β-alanine and L-ornithine.
  • "The findings of this research hold significant implications for the sports nutrition and supplemental protein industries," said Vic Rathi, CEO & Founder of Specialty Enzymes & Probiotics.
  • "Improving digestion and nutrient absorption from supplemental protein, thus maximizing consumer gain, meets a vital need in today's market."

Metabolon and Cardiff University Centre for Neuropsychiatric Genetics and Genomics Forge Alliance to Propel Multiple Sclerosis Research

Retrieved on: 
Mardi, mars 12, 2024
Plasma, Metabolomics, Disease, Multiple sclerosis, CSF, Partnership, Central nervous system, Biomedical Research, Patient, Biomarker, Research, Parkinson's disease, Cerebrospinal fluid, Medicine, Cardiff University, Alzheimer's disease, Pathology, Pharmaceutical industry

MORRISVILLE, N.C., March 12, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced a partnership with Cardiff University Centre for Neuropsychiatric Genetics and Genomics, a renowned institution at the forefront of biomedical research. This collaboration is poised to discover new biomarkers to accelerate advancements in the understanding and treatment of multiple sclerosis (MS).

Key Points: 
  • This collaboration is poised to discover new biomarkers to accelerate advancements in the understanding and treatment of multiple sclerosis (MS).
  • MS is a neuroinflammatory disorder that affects the central nervous system, giving rise to a range of physical and neuropsychological challenges.
  • For years, the Cardiff University Centre for Neuropsychiatric Genetics and Genomics has been following MS patients and developing cutting-edge tools for clinicians and researchers.
  • To learn more about Metabolon's research and development efforts in neurodegeneration diseases, including Alzheimer's, Parkinson's, and MS, visit https://www.metabolon.com/applications/neuroscience/

Metabolon and Cardiff University Centre for Neuropsychiatric Genetics and Genomics Forge Alliance to Propel Multiple Sclerosis Research

Retrieved on: 
Mardi, mars 12, 2024
Plasma, Metabolomics, Disease, Multiple sclerosis, CSF, Partnership, Central nervous system, Biomedical Research, Patient, Biomarker, Research, Parkinson's disease, Cerebrospinal fluid, Medicine, Cardiff University, Alzheimer's disease, Pathology, Pharmaceutical industry

MORRISVILLE, N.C., March 12, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced a partnership with Cardiff University Centre for Neuropsychiatric Genetics and Genomics, a renowned institution at the forefront of biomedical research. This collaboration is poised to discover new biomarkers to accelerate advancements in the understanding and treatment of multiple sclerosis (MS).

Key Points: 
  • This collaboration is poised to discover new biomarkers to accelerate advancements in the understanding and treatment of multiple sclerosis (MS).
  • MS is a neuroinflammatory disorder that affects the central nervous system, giving rise to a range of physical and neuropsychological challenges.
  • For years, the Cardiff University Centre for Neuropsychiatric Genetics and Genomics has been following MS patients and developing cutting-edge tools for clinicians and researchers.
  • To learn more about Metabolon's research and development efforts in neurodegeneration diseases, including Alzheimer's, Parkinson's, and MS, visit https://www.metabolon.com/applications/neuroscience/

Silent cancers: here’s what you need to know when there are no obvious symptoms

Retrieved on: 
Mercredi, avril 3, 2024
Diagnosis, Research, Health, Princess, Metabolism, Colorectal cancer, Prostate cancer, Metabolomics, Disease, Risk, Patient, Biomarker, Weight loss, Perception, Neoplasm, DNA, Breast, Malignancy, Prostate, Mammography, Cancer, Medicine, Woman, Fatigue, HPV, Google Images, CRC, Breast cancer, Large intestine, Blood, Medical imaging

Contrary to common perception, cancer does not always announce its presence through overt symptoms or obvious signs.

Key Points: 
  • Contrary to common perception, cancer does not always announce its presence through overt symptoms or obvious signs.
  • While even silent cancers can sometimes be aggressive and advance rapidly, they can also remain dormant for years or even decades.
  • Some prostate, breast and thyroid cancers, for example, often evolve slowly without obvious symptoms or spreading beyond the original area.

The importance of early diagnosis

  • Whatever the cancer, it’s always important to get an early diagnosis though – and for silent cancers, this is obviously a challenge.
  • But such symptoms can be misinterpreted or easily dismissed, which contributes to delayed diagnosis and treatment.
  • Fortunately, in many countries including the UK, we have screening tests for diseases like breast or colon cancer, to increase early diagnoses.
  • Early diagnosis is a key factor for successful cancer treatment.

Biomarker discovery

  • From molecular profiling to liquid biopsy techniques (blood tests to diagnose cancer), innovative approaches are reshaping the landscape of cancer diagnosis, offering new avenues for personalised and precision medicine.
  • For example, I worked with a team using blood tests to identify cancers in more than 1,000 women recalled after screening for mammography.
  • Although there’s increasing awareness and use of this approach in Europe, it isn’t standard in the UK.


Justin Stebbing does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Wistar Scientists Discover Link Between Leaky Gut and Accelerated Biological Aging

Retrieved on: 
Vendredi, février 23, 2024
Methylation, Dysbiosis, Culture, Penn Center, Health, Bacteria, University, Subtypes of HIV, Life Length, Wistar Institute, Bangladesh Technical Education Board, Ileum, Infection, NIH, AIDS, Glass, Metabolomics, Nucleotide, DSM-IV codes, Biomedical Research, HIV/AIDS research, Wistar, University of Pittsburgh, DNA, Immune system, National Institutes of Health, Leiden University Medical Center, Weill Cornell Medicine, Hannum, Research, Inflammation, Blood, Ageing, Cancer, Cell biology, Microbiome, Rush University, HIV, DNA methylation, Vaccine

Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.

Key Points: 
  • Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.
  • A prime suspect in this aging puzzle is the gut microbiome and its potential leakage into the bloodstream.
  • The Abdel-Mohsen lab investigates how gut leakage can impact the immune system and lead to chronic inflammation, which may accelerate aging.
  • Their analysis revealed a significant connection between disrupted gut microbiomes, increased intestinal permeability (leaky gut), and faster biological aging.

Dr. Ernst J. Schaefer, MD, joins Olaris Inc. as CLIA Laboratory Director

Retrieved on: 
Mardi, mars 5, 2024
Human nutrition, Bangladesh Technical Education Board, Ageing, Research, American Heart Association, Cardiovascular disease, Metabolomics, Health, Tufts University, Society, University, Health care, Medicine, Fluid mechanics, Policy, CLIA, Patient, Machine learning, Nutrition, Publication, Tufts Medical Center, Medical device

FRAMINGHAM, Mass., March 5, 2024 /PRNewswire-PRWeb/ -- Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning for the discovery and development of its myOLARIS™ diagnostics products, announced that Dr. Ernst Schaefer, a 30-year veteran in clinical diagnostics and an expert in developing monitoring tools to improve human health will be joining as CLIA Laboratory Director. Dr. Schaefer will continue in his role as laboratory director for Boston Heart Diagnostics, a company he co-founded in 2007, and at Clinical Enterprise, both in Framingham, MA.

Key Points: 
  • Olaris, Inc. a developer of metabolomic based precision diagnostics is pleased to announce that Dr. Ernst Schaefer, a 30 year veteran in clinical diagnostics and an expert in developing monitoring tools to improve human health will be joining as CLIA Laboratory Director.
  • Dr. Schaefer will continue in his role as laboratory director for Boston Heart Diagnostics, a company he co-founded in 2007, and at Clinical Enterprise, both in Framingham, MA.
  • "Ernie has one of the top clinical diagnostic minds in the world" said Dr. Elizabeth O'Day, CEO and Founder of Olaris.
  • I can't think of a better partner to bring Olaris' innovative diagnostics to the patients that need them".

Clinical Microbiomics adds World-Leading Expertise in Long-Read DNA & RNA Sequencing Technologies with Acquisition of DNASense ApS

Retrieved on: 
Vendredi, mars 1, 2024
Acquisition, Soil, QMS, Animal, CCO, Global health, Metabolomics, RNA, Human, Environment, Quality management system, CSO, Agriculture, Laboratory, Research, DNA, Water, Partnership, Antibiotics

The acquisition expands Clinical Microbiomics' expertise and offering for new segments such as agriculture, industrial, and environmental ecosystems, and it adds cutting-edge long- read DNA- and RNA sequencing technologies to the extensive portfolio of multi-omics technologies for the microbiome field.

Key Points: 
  • The acquisition expands Clinical Microbiomics' expertise and offering for new segments such as agriculture, industrial, and environmental ecosystems, and it adds cutting-edge long- read DNA- and RNA sequencing technologies to the extensive portfolio of multi-omics technologies for the microbiome field.
  • H. Bjørn Nielsen, CSO of Clinical Microbiomics, "DNASense is a first mover in applying long-read technology broadly across microbiome research and industrial applications.
  • Mads Søndergaard, CEO of DNASense, comments on the synergies: "Joining Clinical Microbiomics is a pivotal moment for DNASense.
  • The DNASense acquisition facilitates expansion into new applications of microbiome science to better understand diverse biological systems and ecological dynamics.